BioLineRx Balance Sheet Health
Financial Health criteria checks 5/6
BioLineRx has a total shareholder equity of $13.2M and total debt of $9.8M, which brings its debt-to-equity ratio to 73.9%. Its total assets and total liabilities are $63.9M and $50.7M respectively.
Key information
73.9%
Debt to equity ratio
US$9.77m
Debt
Interest coverage ratio | n/a |
Cash | US$42.99m |
Equity | US$13.22m |
Total liabilities | US$50.70m |
Total assets | US$63.93m |
Recent financial health updates
Recent updates
BioLineRx stock slips on $15M securities offering
Sep 19BioLineRx files for FDA approval of motixafortide in stem cell mobilization
Sep 12biolinerx GAAP EPS of -$0.01 beats by $0.08
Aug 16BioLineRx, GenFleet to co-develop Motixafortide treatment for a type of pancreatic cancer
Jun 29BioLineRx: A Top Candidate For A Takeover Before 2022 Ends
Jun 30biolinerx EPS beats by $0.17
May 26BioLineRx (BLRX) shares rocket 73% on positive Motixafortide data in multiple myeloma
May 04BioLineRx jumps 22% on promising triple combination data of motixafortide in pancreatic cancer
Dec 16biolinerx EPS beats by $0.32
Nov 23BioLineRx launches early-stage study with lead asset in COVID-19 related respiratory distress
Nov 18BioLineRx launches mid-stage combo study in first-line pancreatic cancer
Oct 29Financial Position Analysis
Short Term Liabilities: BLRX's short term assets ($47.2M) exceed its short term liabilities ($30.9M).
Long Term Liabilities: BLRX's short term assets ($47.2M) exceed its long term liabilities ($19.9M).
Debt to Equity History and Analysis
Debt Level: BLRX has more cash than its total debt.
Reducing Debt: BLRX's debt to equity ratio has increased from 21.1% to 73.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BLRX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: BLRX has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 0.4% each year.